Pseudomonas aeruginosa bacteremia in children over ten consecutive years: Analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes

Journal of Korean Medical Science

Volumn 26, Issue 5, 2011, Pages 612-618

  Yang, Mi Ae ^a   Lee, Jina ^b   Choi, Eun Hwa ^a,c   Lee, Hoan Jong ^a,c  

^a Seoul National University Children's Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Bacteremia; Clinical outcome; Drug resistance; Multiple; Pseudomonas aeruginosa

Indexed keywords

ADOLESCENT; ARTICLE; BACTEREMIA; CHILD; DRUG EFFECT; FEMALE; HUMAN; INFANT; INTENSIVE CARE UNIT; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; NEWBORN; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA; TEACHING HOSPITAL; TREATMENT OUTCOME;

ADOLESCENT; BACTEREMIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITALS, TEACHING; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS, PEDIATRIC; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79955588785     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.5.612     Document Type: Article

References (29)

1. Pier GB, Ramphal R. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious diseases, 6th ed. Philadelphia: Churchill Livingstone 2005; 2587-615.
2. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999; 28: 1128-33.
3. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with diferent antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-82.
4. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004; 57: 112-8.
5. Kuikka A, Valtonen V V. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17: 701-8.
6. Wisplinghof H, Bischof T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
7. Hauser AR, Cobb E, Bodi M, Mariscal D, Vallés J, Engel JN, Rello J. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30: 521-8.
8. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, Sawa T, Frank DW, Wiener-Kronish JP. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183: 1767-74.
9. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160: 501-9.
10. Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno J P, Grafunder E, Lomaestro B, McGregor JC. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51: 3510-5.
11. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: 1306-11.
12. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37: 745-51.
13. Fergie JE, Shema SJ, Lott L, Crawford R, Patrick CC. Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with a poor outcome. Clin Infect Dis 1994; 18: 390-4.
14. Grisaru-Soen G, Lerner-Geva L, Keller N, Berger H, Passwell JH, Barzilai A. Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors. Pediatr Infect Dis J 2000; 19: 959-63.
15. Huang YC, Lin TY, Wang CH. Community-acquired Pseudomonas aeruginosa sepsis in previously healthy infants and children: analysis of forty-three episodes. Pediatr Infect Dis J 2002; 21: 1049-52.
16. Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, Cellini M, Frenos S, Milano GM, Cappelli B, Licciardello M, Beretta C, Aricò M, Castagnola E; Infection Study Group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 2010; 95: 1612-5.
17. Suárez C, Peña C, Tubau F, Gavaldà L, Manzur A, Dominguez MA, Pujol M, Gudiol F, Ariza J. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections. J Infect 2009; 58: 285-90.
18. Valoor HT, Singhi S, Jayashree M. Low-dose hydrocortisone in pediatric septic shock: an exploratory study in a third world setting. Pediatr Crit Care Med 2009; 10: 121-5.
19. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC. Bloodstream infections by extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46: 1481-91.
20. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. Document M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
22. Johnson LE, D'Agata EM, Paterson DL, Clarke L, Qureshi ZA, Potoski BA, Peleg AY. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis 2009; 11: 227-34.
23. Gülay Z, Atay T, Amyes SG. Clonal spread of imipenem-resistant Pseudomonas aeruginosa in the intensive care unit of a Turkish hospital. J Chemother 2001; 13: 546-54.
24. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. Te effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155: 1699-704.
25. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. J Infect Dis 1994; 170: 1622-5.
26. Tacconelli E, Tumbarello M, Bertagnolio S, Citton R, Spanu T, Fadda G, Cauda R. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. Emerg Infect Dis 2002; 8: 220-1.
27. Chen HY, Yuan M, Ibrahim-Elmagboul IB, Livermore DM. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 35: 521-34.
28. Karlowsky JA, Draghi DC, Jones ME, Tornsberry C, Friedland IR, Sahm D F. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1681-8.
29. Vidal F, Mensa J, Almela M, Martinez JA, Marco F, Casals C, Gatell JM, Soriano E, Jimenez de Anta M T. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156: 2121-6.